Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs DCGO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DCGO Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)
DCGO Overall Winner
6-Pillar Tally: MXCT 1 – 5 DCGO
Matrix Metrics: MXCT 5 – 5 DCGO
As of Nov 20, 2026, DocGo Inc. (DCGO) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCGO carries 44.8/100 (HOLD) at $0.17 (60.2x Forward P/E, -29.0% operating margin).
- Growth vs. Quality Trade-Off: DCGO earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. MXCT 41.7/100 SELL) and 1.35β · 108% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile DCGO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MXCT vs DCGO
MXCT
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
DCGO
Head-to-Head Winner
DocGo Inc. Common Stock
$0.17
+1.98% 1D
Market Cap
$17.0M
TTM Revenue
$297M
Forward P/E
60.2x
Beta / 30D Vol
1.35β · 108% Vol
Unified Composite Score
44.8
HOLD
Tech 45.0
Fund 56.0
Flow 69.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 5 DCGO)
1. Valuation Multiples
DCGO
Forward P/E
N/M
60.2x
Trailing P/E
N/M
60.2x
PEG Ratio
N/M
N/M
EV / Revenue
3.9x
0.1x
2. Growth & Scale
MXCT
Revenue Growth (YoY)
+48.7%
+3.7%
Earnings Growth (YoY)
+0.0%
+9.0%
TTM Revenue (USD)
$34M
$297M
Market Cap
$132.2M
$17.0M
3. Profitability & Quality
DCGO
Gross Margin
81.0%
32.0%
Operating Margin
-85.5%
-29.0%
Net Profit Margin
-81.4%
-61.0%
Return on Equity (ROE)
-16.9%
-115.0%
4. Balance Sheet & Cash Flow
DCGO
Cash Generation (TTM)
-$24M
-$29M
Cash Flow Margin
-69.2%
-9.6%
Net Cash / Leverage
$2.2M Net Debt (0.11x D/E)
$672,808 Net Debt (0.22x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCGO
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
0.2% (<1st %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
DCGO
OpEx & R&D Intensity
N/A
61.0% of Rev ($181M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Care Facilities Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MXCT (5) vs DCGO (5)| Institutional Metric | MXCT | DCGO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $132.2M | $17.0M | MXCT | |
| Trailing P/E Ratio | N/M | 60.2x | DCGO | |
| Forward P/E Ratio | N/M | 60.2x | DCGO | |
| Revenue Growth (YoY) | +48.7% | +3.7% | MXCT | |
| Operating Margin (TTM) | -85.5% | -29.0% | DCGO | |
| Net Profit Margin | -81.4% | -61.0% | DCGO | |
| Return on Equity (ROE) | -16.9% | -115.0% | MXCT | |
| 52-Week Range Position | 63% ($1–$2) | 1% ($0–$1) | MXCT | |
| Beta / 30D Volatility | 1.19β · 96% Vol | 1.35β · 108% Vol | MXCT | |
| Unified Institutional Score | 41.7 / 100 (SELL) | 44.8 / 100 (HOLD) | DCGO | |
| Trailing 12M Revenue (USD) | $34M | $297M | Scale | |
| Gross Profit Margin (TTM) | 81.0% | 32.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | N/M PEG · 0.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($2.2M Net Debt (0.11x D/E)) | -$29M ($672,808 Net Debt (0.22x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MXCT +31.01 pp
3M Horizon
MXCT +52.7 pp
6M Horizon
MXCT +103.97 pp
1Y Horizon
MXCT +61.53 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | DCGO Revenue | MXCT Op. Margin | DCGO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -93.7% | N/A | MXCT |
| FY2020 | $20M | $90M | -71.6% | -15.7% | DCGO |
| FY2021 | $20M | $320M | -84.3% | 4.8% | DCGO |
| FY2022 | $30M | $440M | -95.2% | 5.0% | DCGO |
| FY2023 | $20M | $620M | -247.7% | 2.4% | DCGO |
| FY2024 | $20M | $620M | -230.5% | 4.7% | DCGO |
| FY2025 | $20M | $320M | -247.6% | -55.3% | DCGO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DCGO
UNCLASSIFIED
Current IV
0.2%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DCGO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DCGO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
OpEx & R&D Reinvestment
61.0% of Rev ($181M)
90D Engineering Disclosures
0 Published
Investor FAQ MXCT vs DCGO Key Questions & Quantitative Answers
As of Nov 20, 2026, DocGo Inc. (DCGO) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCGO carries 44.8/100 (HOLD) at $0.17 (60.2x Forward P/E, -29.0% operating margin). Growth vs. Quality Trade-Off: DCGO earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. MXCT 41.7/100 SELL) and 1.35β · 108% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile DCGO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MXCT leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with DCGO at +3.7% YoY revenue growth and +9.0% YoY earnings growth on $297M TTM revenue (32.0% gross margin, -29.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while DCGO shifted +255.6%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 61.0% of Rev ($181M) (0 disclosures) for DCGO.
DCGO screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas DCGO trades at 60.2x Forward P/E, 60.2x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-9.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus DCGO (-115.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, DCGO carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 108% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DCGO vs MXCT · Reverse Pair
MXCT vs CTKB
· Sector Peer
MXCT vs SGHT
· Sector Peer
MXCT vs TMCI
· Sector Peer
DCGO vs CTKB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma